Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. (Q51360460)

4 April 2018

title

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. (English)

1 reference

4 April 2018

0 references

1 reference

0 references

C Pan

1

1 reference

4 April 2018

X Xing

2

1 reference

4 April 2018

P Han

3

1 reference

4 April 2018

S Zheng

4

1 reference

4 April 2018

J Ma

5

1 reference

4 April 2018

J Liu

6

1 reference

4 April 2018

X Lv

7

1 reference

4 April 2018

J Lu

8

1 reference

4 April 2018

G Bader

9

1 reference

4 April 2018

Institution Investigators

10

1 reference

4 April 2018

publication date

1 April 2012

1 reference

4 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

4 April 2018

volume

14

1 reference

4 April 2018

issue

8

1 reference

4 April 2018

page(s)

737-744

1 reference

4 April 2018

Prevalence of diabetes among men and women in China

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

The status of diabetes control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01593.X

10.1111/J.1463-1326.2012.01593.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

release_jyfxfbjpjjcxlof6urphsv7h6a

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jyfxfbjpjjcxlof6urphsv7h6a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

4 April 2018